Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 238Carcinoma, Non-Small-Cell Lung 205Prostatic Neoplasms 137Lung Neoplasms 96Stomach Neoplasms 85Head and Neck Neoplasms 59Squamous Cell Carcinoma of Head and Neck 58Neoplasms 42Neoplasm Metastasis 39Esophageal Neoplasms 36Ovarian Neoplasms 29Pancreatic Neoplasms 27Sarcoma 19Urinary Bladder Neoplasms 18Adenocarcinoma of Lung 18Carcinoma, Squamous Cell 17Triple Negative Breast Neoplasms 15Nasopharyngeal Carcinoma 14Adenocarcinoma 14Carcinoma, Ovarian Epithelial 13Adenocarcinoma Of Esophagus 13Recurrence 12Inflammatory Breast Neoplasms 10Carcinoma, Transitional Cell 10Breast Neoplasms, Male 10Esophageal Squamous Cell Carcinoma 9Laryngeal Neoplasms 8Uterine Cervical Neoplasms 7Nasopharyngeal Neoplasms 7Leiomyosarcoma 7

Interventions

Gemcitabine 9Carboplatin 8Paclitaxel 6Capecitabine 4Bevacizumab 4pembrolizumab 3Irinotecan 3Erlotinib Hydrochloride 3atezolizumab 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Filgrastim 2Cisplatin 2CP protocol 2tislelizumab 1tegafur-gimeracil-oteracil 1spartalizumab 1sintilimab 1pertuzumab 1pemigatinib 1olaparib 1ivosidenib 1ipatasertib 1etoposide phosphate 1entrectinib 1cobimetinib 1belinostat 1antineoplaston AS 2-1 1antineoplaston A10 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms, Unknown Primary × Docetaxel × Clear all
NCT00119314 2015-05-27

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

Rutgers, The State University of New Jersey

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡